Preview

Злокачественные опухоли

Расширенный поиск

ВЫБОР ПОСЛЕДОВАТЕЛЬНОСТИ КОМБИНАЦИЙ ХИМИОПРЕПАРАТОВ И МОНОКЛОНАЛЬНЫХ АНТИТЕЛ В ЛЕЧЕНИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИ

https://doi.org/10.18027/2224-5057-2018-8-2-50-59

Полный текст:

Аннотация

В настоящем обзоре литературы проанализированы работы, посвящённые выбору терапии первой и последующих линий лечения у больных метастатическим раком толстой кишки. Обсуждены данные по результатам сочетания таргетных моноклональных антител с различными режимами химиотерапии. Освещены современные исследования по тактике выбора последовательности таргетной терапии у больных с метастатическим заболеванием. Также рассмотрены вопросы влияния различных факторов на эффективность терапии теми или иными препаратами и их места в выборе терапии при раке толстой кишки.

Об авторах

М. Ю. Федянин
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Министерства здравоохранения РФ
Россия

Михаил Ю. Федянин - кандидат медицинских наук, старший научный сотрудник отделения клинической фармакологии и химиотерапии.

Москва



С. А. Тюляндин
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Министерства здравоохранения РФ
Россия

Сергей А. Тюляндин, доктор медицинских наук, профессор, зав. отделением клинической фармакологии и химиотерапии.

Москва



Список литературы

1. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004. Vol. 22 (2). P. 229–237. doi: 10.1200/JCO. 2004.05.113.

2. Состояние онкологической помощи населению России в 2014 году / Под ред. Каприна А. Д., Старинского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2015.

3. Федянин М. Ю., Трякин А. А., Тюляндин С. А. Адъювантная химиотерапия при раке ободочной кишки. Фарматека. 2011. № 7 (220). C. 21–27.

4. Yamazaki K., Nagase M., Tamagawa H. et al. A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). J. Clin. Oncol. 2014. Vol. 32. P. 5s (suppl; abstr 3534).

5. Falcone A., Cremolini C., Masi G. et al. FOLFOXIRI / bevacizumab (bev) versus FOLFIRI / bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. J. Clin. Oncol. 2013. Vol. 31 (suppl; abstr 3505).

6. de Gramont A. H., Chibaudel L. B., Bourges O. et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J. Clin. Oncol. 2009. Vol. 27. P. 15s (suppl; abstr 4024).

7. Grothey A., Sargent D., Goldberg R. M., Schmoll H. J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 2004. Vol. 22 (7). P. 1209– 1214. doi: 10.1200/JCO.2004.11.037.

8. Madi A., Fisher D., Wilson R. H., Adams R. A. et al. Oxaliplatin / capecitabine vs oxaliplatin / infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br. J. Cancer. 2012. Vol. 107 (7). P. 1037–1043. doi: 10.1038/bjc.2012.384.

9. Tveit K. M., Guren T., Glimelius B., Pfeiffer P. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 2012. Vol. 30 (15). P. 1755–1762. doi: 10.1200/JCO.2011.38.0915.

10. Ku G. Y., Haaland B. A., Lopes G. de L. Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother. Pharmacol. 2012. Vol. 70. P. 231–238. doi: 10.1007/s00280-012-1898-7.

11. Bijnsdorp I. V., Kruyt F. A., Fukushima M., Smid K., Gokoel S., Peters G. J. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Sci. 2010. Vol. 101. P. 440–447. doi: 10.1111/j.1349–7006.2009.01375.x.

12. Kim H. P., Yoon Y. K., Kim J. W., Smid K., Gokoel S., Peters G. J. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009. Vol. 4. e5933.

13. Douillard J. Y., Siena S., Cassidy J., Tabernero J., Burkes R. et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2014. Vol. 25 (7). P. 1346–1355. doi: 10.1093/annonc/mdu141.

14. Wen F., Tang R., Sang Y., Li M., Hu Q., Du Z., Zhou Y. et al. Which is false: Oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. Cancer Sci. 2013. Vol. 104. No. 10. P. 1330–1338. doi: 10.1111/cas.12224.

15. Ku G. Y., Haaland B. A., de Lima Lopes G. Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother. Pharmacol. 2012. Vol. 70. P. 231–238. doi: 10.1007/s00280-012-1898-7.

16. Venook A. P., Niedzwiecki D., Lenz H. J., Innocenti F. et al. Cancer and Leukemia Group B (Alliance), SWOG, and ECOG. CALGB / SWOG 80405: Phase III trial of irinotecan / 5-FU / leucovorin (FOLFIRI) or oxaliplatin / 5-FU / leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 2014. Vol. 32. P. 5s (suppl; abstr LBA3).

17. Федянин М. Ю., Трякин А. А., Тюляндин С. А. Химиотерапия больных метастатическим раком толстой кишки // Онкологическая колопроктология. 2012. № 2. C. 26–34. doi: http://dx.doi.org/10.17650/2220-3478-2012-0-2-26-34.

18. Carrasco J., Gizzi M., Pairet G., Lannoy V. et al. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Br. J. Cancer. 2015. Vol. 113 (9). P. 1298–1304. doi: 10.1038/bjc.2015.321.

19. Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012. Vol. 30 (28). P. 3499–3506. doi: 10.1200/JCO.2012.42.8201.

20. Tabernero J., Yoshino T., Cohn A. L., Obermannova R. et al. Ramucirumab versus placebo in combination with second line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015. Vol. 16 (5). P. 499–508. doi: 10.1016/S1470–2045(15)70127-0.

21. Folprecht G., Pericay C., Saunders M. P., Thomas A. et al. Oxaliplatin and 5-FU / folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol. 2016 Apr 18. pii: mdw176. [Epub ahead of print]. doi: 10.1093/annonc/mdw176.

22. Enzinger P. C., McCleary N. J., Zheng H., Enzinger P. C. et al. Multicenter double-blind randomized phase II: FOLFOX + zivaflibercept / placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA). J. Clin. Oncol. 2016. Vol. 34 (suppl 4S; abstr 4).

23. Chiron M. V. P., Lejeune P., Demers B., Leopold D., Bissery M. C. Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models. Proceeding from AACR-NCI-EORTC: Molecular Targets and Cancer Therapeutics. 2007. Abstract A13. San Francisco, Calif, USA.

24. Yoon H. H., Bendell J. C., Braiteh F. S., Firdaus I. et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J. Clin. Oncol. 2014. Vol. 32. P. 5s (suppl; abstr 4004).

25. ESMO draft mCRC treatment algorithm presented at WCGIC 2015.

26. Khattak M. A., Martin H., Davidson A., Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin. Colorectal Cancer. 2015. Vol. 14 (2). P. 81–90. doi: 10.1016/j.clcc.2014.12.011.

27. Rivera F., Karthaus M., Hecht J. R., Fasola G. et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST. J. Clin. Oncol. 2015. Vol. 33 (suppl 3; abstr 660).

28. Heinemann V., Stintzing S., Modest D. P. et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur. J. Cancer. 2015. Vol. 51 (14). P. 1927–1236. doi: 10.1016/j.ejca. 2015.06.116

29. Venook A. P., Niedzwiecki D., Innocenti F., Fruth B. et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). J. Clin. Oncol. 2016. Vol. 34 (suppl; abstr 3504).

30. Lee M. S., Advani S. M., Morris J., Jiang Z. Q. et al. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor ( EGFR) therapy. J. Clin. Oncol. 2016. Vol. 34 (suppl; abstr 3506).

31. Grothey A., Sugrue M. M., Purdie D. M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 2008. Vol. 26 (33). P. 5326–5334. doi: 10.1200/JCO.2008.16.3212.

32. Bendell J. C., Bekaii-Saab T. S., Cohn A. L. et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012. Vol. 17 (12). P. 1486–1495. doi: 10.1634/theoncologist.2012-0190.

33. Bennouna J., Sastre J., Arnold D., sterlund P. et al.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013. Vol. 14 (1). P. 29–37. doi: 10.1016/S1470–2045(12)70477-1.

34. Masi G., Loupakis F., Salvatore L., Cremolini C. et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO). J. Clin. Oncol. 2013. Vol. 31 (suppl; abstr 3615).

35. Kopetz S., Hoff P. M., Morris J. S., Wolff R. A. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010. Vol. 28 (3). P. 453–459. doi: 10.1200/JCO.2009.24.8252.

36. Loupakis F., Cremolini C., Fioravanti A. et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br. J. Cancer. 2011. Vol. 104 (8). P. 1262–1269. doi: 10.1038/bjc.2011.85.

37. Masi G., Loupakis F., Salvatore L. et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010. Vol. 11. P. 845–852. doi: 10.1016/S1470–2045(10)70175-3.

38. Chau I., Joulain F., Iqbal S. U., Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014. Vol. 14. P. 605. doi:10.1186/1471-2407-14-605.

39. Viloria-Petit A., Crombet T., Jothy S., Hicklin D. et al. Acquired resistance to the antitumor effect of epidermal growth factor receptorblocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001. Vol. 61 (13). P. 5090–5101.

40. Norguet E., Dahan L., Gaudart J., Gasmi M., Ouafik L., Seitz J. F. Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence? Dig. Liver Dis. 2011. Vol. 43 (11). P. 917–919. doi: 10.1016/j.dld.2011.06.002.

41. Cascinu S., Zaniboni A., Lonardi., Hicklin D. et al. Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI / bevacizumab. J. Clin. Oncol. 2016. Vol. 34 (suppl 4S; abstr 632).

42. Hiret S., Christophe B., Bertaut A., Bouche O. et al. Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18-UNICANCER GI). J. Clin. Oncol. 2016. Vol. 34 (suppl; abstr 3514).

43. Hecht J. R., Cohn A., Dakhil S., Saleh M. et al. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin. Colorectal. Cancer. 2015. Vol. 14 (2). P. 72–80. doi: 10.1016/j.clcc.2014.12.009.

44. Peeters M., Price T. J., Cervantes A., Sobrero A. F. et al. Final results from a randomized phase 3 study of FOLFIRI {+ / -} panitumumab for second-line treatment of metastatic colorectal cancer. Ann. Oncol. 2014. Vol. 25 (1). P. 107–116. doi: 10.1093/annonc/mdt523.

45. Peeters M., Kim T. W., Li J., Cascinu S., Ruff P. et al. Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. J. Clin. Oncol. 2016. Vol. 34 (suppl 4S; abstr 519).

46. Ciardiello F., Bianco R., Caputo R., Caputo R. et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 2004. Vol. 10 (2). P. 784–93. doi: 10.1158/1078-0432.CCR-1100-03.

47. Bianco R., Rosa R., Damiano V., Daniele G. et al. Vascular endothelial growth factor receptor-1 contributes to resistance to antiepidermal growth factor receptor drugs in human cancer cells. Clin. Cancer Res. 2008. Vol. 14 (16). P. 5069–5080. doi: 10.1158/1078-0432.CCR-07-4905.

48. Lam K. O., Lee V. H., Liu R. K., Leung T. W., Kwong D. L. Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. Oncol. Lett. 2013. Vol. 5 (2). P. 637–640. doi: 10.3892/ol.2012.1045.

49. Modest D.P., Stintzing S., von Weikersthal L.F., Decker T. et al. Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. J. Clin. Oncol. 2014. Vol. 32. P. 5s (suppl; abstr 3558).

50. Rivera F., Schwartzberg L. S., Karthaus M. et al. Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). J. Clin. Oncol. 2014. Vol. 32. P. 5s (suppl; abstr 3629).

51. Siravegna G., Mussolin B., Buscarino M. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015. Vol. 21. P. 795-801. doi: 10.1038/nm.3870.


Для цитирования:


Федянин М.Ю., Тюляндин С.А. ВЫБОР ПОСЛЕДОВАТЕЛЬНОСТИ КОМБИНАЦИЙ ХИМИОПРЕПАРАТОВ И МОНОКЛОНАЛЬНЫХ АНТИТЕЛ В ЛЕЧЕНИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИ. Злокачественные опухоли. 2018;8(2):50-59. https://doi.org/10.18027/2224-5057-2018-8-2-50-59

For citation:


Fedyanin M.Y., Tjulandin S.A. OPTIMAL SEQUENCES AND COMBINATION OF CHEMOTHERAPY AND MONOCLONAL ANTIBODIES IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER. Malignant tumours. 2018;8(2):50-59. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-2-50-59

Просмотров: 232


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)